Research Article
Genomic and Immunological Characterization of Pyroptosis in Lung Adenocarcinoma
Figure 6
Prediction of response to immunotherapy and chemotherapy in patients with different PPRS. (a-c) The expression of 21 immune checkpoints between high-PPRS group and low-PPRS group in TCGA-LUAD (a), GSE31210 (b) and GSE72094 (c) cohorts. (d) The relative frequency of immune checkpoints expressed highest in the high-PPRS group. (e) Differences for samples with different PPRS in myeloid-derived suppressor cells (MDSC), cancer associated fibroblasts (CAF), M2 macrophages (TAM.M2), T cell exclusion, T cell dysfunction, TIDE scores. (f) Comparison for sensitivity of Paclitaxel, Cisplatin, Docetaxel and Vinorelbine in high- and low-PPRS groups of LUAD samples. Wilcoxon test was conducted. ns, no significance. , , , .
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |